Bioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2
Citations Over TimeTop 1% of 2004 papers
Abstract
Self-immolative dendrimers have recently been developed and introduced as a potential platform for a multi-prodrug. These unique structural dendrimers can release all of their tail units, through a self-immolative chain fragmentation, which is initiated by a single cleavage at the dendrimer's core. Incorporation of drug molecules as the tail units and an enzyme substrate as the trigger can generate a multi-prodrug unit that will be activated with a single enzymatic cleavage. We have synthesized the first generation of dendritic prodrugs with doxorubicin and camptothecin as tail units and a retro-aldol retro-Michael focal trigger, which can be cleaved by catalytic antibody 38C2. The bioactivation of the dendritic prodrugs was evaluated in cell-growth inhibition assay with the Molt-3 leukemia cell line in the presence and the absence of antibody 38C2. The dendritic unit was applied as a platform for a heterodimeric prodrug, which achieved a remarkable increase in toxicity with its bioactivation.
Related Papers
- → The dendritic effect illustrated with phosphorus dendrimers(2014)129 cited
- Dendrimers in medicine and biotechnology. New molecular tools(2006)
- → Supramolecular Crafting of Self-Assembling Camptothecin Prodrugs with Enhanced Efficacy against Primary Cancer Cells(2016)66 cited
- → [Research progress on camptothecin and its derivative nano-prodrugs based on tumor microenvironment response].(2022)2 cited
- → Syntheses of Dendrimers and Dendrons(2011)6 cited